PET scan to guide immunotherapy in advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial uses a special PET scan to see how immune cells (CD8 T cells) are working in your tumor before you start a PD-1 immunotherapy drug (nivolumab or cetrelimab). The goal is to find out if the scan can predict whether the immunotherapy will work for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that has spread or cannot be removed with surgery, and your doctor thinks PD-1 immunotherapy might help.
- Your cancer has progressed after at least one previous treatment, or there is no better standard option.
- You can have a biopsy (tissue sample) taken from your tumor safely.
- Your overall health is good (ECOG score 0 or 1), meaning you are fully active or only slightly restricted in physical activity.
- You have not had immunotherapy (like Keytruda or Opdivo) before, and you do not have an active autoimmune disease or recent treatment with strong immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a special imaging medicine to see how tumors and immune activity respond when you’re treated with cemiplimab (a PD-1 immunotherapy). It may help doctors better understand who benefits from PD-1 treatment by tracking where the medicine goes in the body.
This study uses special PET scans to see how well your immune cells respond to immunotherapy given before surgery for non-small cell lung cancer. The goal is to learn which patients benefit most from this treatment approach.
This study uses special PET imaging to measure changes in a marker ([18F]F-AraG) in non-small cell lung cancer after starting anti–PD-1 treatment. It aims to learn whether these scan changes reflect how the cancer responds.
This trial uses a special scan (PET/CT) with an imaging agent that targets a protein called Granzyme B, which is produced by active immune cells. The scan helps doctors see how well immunotherapy is working in your tumor. You may join if you are about to start immunotherapy for a solid tumor and have not had prior cancer treatment.
This trial tests a special PET scan that tracks immune activity to see if it can help monitor how well immunotherapy is working in people with various cancers. It is for patients about to start immunotherapy for the first time.
This study tests a new imaging method to see if a special 'tracer' can light up tumors that have a protein called PD-L1, which is a target for immunotherapy. By taking a PET scan, doctors hope to predict whether immunotherapy will work for you.
Hear when a new Locally Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.